Revvity (NYSE:RVTY) Releases Earnings Results, Beats Estimates By $0.15 EPS

Revvity (NYSE:RVTY) announced its quarterly earnings data on Monday. The company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.55 by $0.15, Briefing.com reports. The business had revenue of $772.06 million during the quarter, compared to analyst estimates of $759.81 million. Revvity had a return on equity of 7.52% and a net margin of 8.44%.Revvity’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same period last year, the company earned $1.42 earnings per share. Revvity updated its FY 2026 guidance to 5.350-5.450 EPS.

Here are the key takeaways from Revvity’s conference call:

• Revvity closed Q4 with stronger-than-expected results—Q4 organic growth of 4% and adjusted EPS of $1.70, while full-year adjusted EPS of $5.06 topped guidance; management repurchased over $800M of shares in 2025 (>$1.5B since 2023).
• 2026 initial guidance is conservative — management forecasted 2%–3% organic growth, total revenue of $2.96B–$2.99B, 28% adjusted operating margin, and adjusted EPS of $5.35–$5.45, but said upside is possible if end markets improve.
• Diagnostics drove Q4 strength (diagnostics organic +7%), led by reproductive health and immunodiagnostics, while life-sciences reagents were flat and instruments showed a meaningful sequential recovery, signaling improving demand trends.
• Strategic software push — Revvity launched the Signals Synthetica AI platform, closed the ACD/Labs acquisition (expected to add ≈$20M revenue / ~75bps), and announced a collaboration with Lilly to accelerate adoption of its Signals software.
• Ongoing headwinds — DRG-related volume pressures in China are expected to persist through about the end of Q2, and Q1 adjusted operating margins are guided down to about 23% due to an extra operating week, tariffs, and cost programs not yet fully implemented.

Revvity Stock Performance

RVTY opened at $106.98 on Tuesday. The company has a quick ratio of 1.44, a current ratio of 1.75 and a debt-to-equity ratio of 0.36. The stock’s 50 day moving average price is $104.09 and its two-hundred day moving average price is $95.52. The firm has a market capitalization of $12.13 billion, a P/E ratio of 53.76, a price-to-earnings-growth ratio of 3.32 and a beta of 1.06. Revvity has a 12-month low of $81.36 and a 12-month high of $126.57.

Revvity Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 8th. Investors of record on Friday, April 17th will be given a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Friday, April 17th. Revvity’s payout ratio is currently 14.07%.

Revvity announced that its Board of Directors has authorized a stock repurchase plan on Monday, October 27th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the company to reacquire up to 8.7% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s leadership believes its shares are undervalued.

Institutional Investors Weigh In On Revvity

Several hedge funds and other institutional investors have recently modified their holdings of RVTY. FORA Capital LLC bought a new stake in shares of Revvity in the third quarter valued at about $525,000. Schroder Investment Management Group increased its stake in Revvity by 5.0% during the third quarter. Schroder Investment Management Group now owns 4,751 shares of the company’s stock valued at $416,000 after acquiring an additional 225 shares during the period. Orion Porfolio Solutions LLC raised its holdings in Revvity by 58.9% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 4,765 shares of the company’s stock valued at $461,000 after acquiring an additional 1,767 shares in the last quarter. State of Wyoming acquired a new position in Revvity in the 2nd quarter valued at approximately $402,000. Finally, Curi Capital LLC bought a new stake in shares of Revvity in the 2nd quarter worth approximately $361,000. Institutional investors and hedge funds own 86.65% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Evercore ISI reissued an “outperform” rating on shares of Revvity in a research note on Monday, January 5th. Robert W. Baird lifted their target price on shares of Revvity from $122.00 to $123.00 and gave the company an “outperform” rating in a research note on Tuesday, October 28th. Weiss Ratings reissued a “sell (d)” rating on shares of Revvity in a research report on Monday, December 29th. Jefferies Financial Group restated a “hold” rating and set a $105.00 price target on shares of Revvity in a report on Monday. Finally, Guggenheim began coverage on shares of Revvity in a research note on Wednesday, October 15th. They issued a “neutral” rating for the company. Five investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Revvity currently has a consensus rating of “Hold” and a consensus price target of $110.55.

Key Headlines Impacting Revvity

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Q4 results beat expectations — adjusted EPS $1.70 (vs. consensus ~ $1.55) and revenue $772.1M, up 5.9% year-over-year, showing improving top- and bottom-line momentum. Revvity Stock Up as Q4 Earnings Beat, Revenues In Line With Estimates
• Positive Sentiment: Company raised FY2026 guidance — EPS guidance of $5.35–$5.45 and ~ $3.0B revenue guidance that sit above Street estimates, signaling management confidence in diagnostics strength. Revvity forecasts 2026 profit, revenue above estimates after blowout fourth quarter
• Positive Sentiment: Immediate market reaction was positive as investors pushed the stock higher on the beat + outlook, supported by analyst notes highlighting the upside. Revvity, Inc. (RVTY) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Management call/transcripts and slide deck are available — useful for investors wanting detail on segment trends, margin drivers and cadence of growth. Revvity (RVTY) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Valuation debate: recent share weakness has prompted DCF/analyst pieces arguing the stock may be attractive vs. intrinsic value, but opinions vary — this may support longer-term buyers more than short-term traders. Is Revvity (RVTY) Attractive After Recent Share Price Weakness And DCF Valuation Gap
• Negative Sentiment: Headwinds remain in academic research funding, which could pressure parts of the business even as diagnostics performs well — a risk to sustaining growth across all segments. Revvity forecasts 2026 profit, revenue above estimates after blowout fourth quarter

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.